Inspira Technologies this week announced it appointed Adi Rizansky Nir as chief medical officer.
Nir will play a critical role in overseeing and guiding Inspira’s medical operations and strategic initiatives. She will collaborate closely with the company’s executive leadership team, medical stage and scientific advisory board to develop and implement innovative strategies that enhance patient outcomes, streamline clinical operations and promote evidence-based practices.
“I am honored to be appointed to the position of CMO. I look forward to contributing to its mission of developing exceptional healthcare treatments, aimed at revolutionizing the treatment offered to acute respiratory patients worldwide,” Nir said in a news release. “I also look forward to directing the development of clinical strategies and planning the Company’s pipeline with the dedicated and talented team of healthcare leaders to drive innovation, improve patient outcomes, and elevate the standard of care in this growing medical sector.”
She has numerous years of experience in both clinical development and healthcare leadership and has a deep understanding of the challenges and opportunities in today’s evolving healthcare industry.
According to the company, Nir has made significant contributions to clinical research and advancements in multiple therapeutic areas. She has extensive experience in clinical strategy implementation and in the scientific and commercial evaluation of R&D assets. Nir has specialized in health economics, market evaluation and the financial valuation of pharmaceutical assets, medical devices and digital health products.
Nir joined the company in 2021 and has significantly contributed to the company’s clinical strategy and product development activities.
“We are thrilled to have Dr. Nir as our new CMO. With her vast experience and exceptional leadership skills, we are confident that she will further strengthen our commitment to delivering high-quality care and advancing our organization’s mission of improving treatments for Acute Respiratory Care,” CEO Dagi Ben Noon said in a news release. “Inspira Technologies has an important year ahead with our planned U.S. Food and Drug Administration (FDA) submission, clinical trial planning, and clinical development. Dr. Nir’s appointment to the position of CMO will be key in successfully advancing the potential regulatory approval and clinical adoption of our products.”